Moderna, Inc. (MRNA)
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot
Immatics (IMTX) remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline. IMTX's valuation reflects high expectations, with the PRAME franchise and next-generation assets like IMA402 representing key upside optionality. SUPRAME's mid-2026 interim update is a pivotal go/no-go catalyst, but unlikely to deliver a near-term stock-moving data readout.
Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom
Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP technology, ensuring freedom to operate for its infectious disease and vaccine pipeline, including future combo vaccines. The settlement preserves MRNA's strong balance sheet, with projected 2026 liquidity of $5.4–$5.9 billion, supporting pipeline expansion and breakeven target by 2028.
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.
Moderna to pay up to $2.25B to settle COVID vaccine patent matter
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) stock added almost 9% after it was announced that the drugmaker has agreed to pay up to $2.25 billion to settle a global patent infringement lawsuit brought by Arbutus Biopharma and Genevant Sciences over the use of lipid nanoparticle (LNP) delivery technology in its COVID-19 and RSV vaccines. The settlement resolves all US and international enforcement actions related to Moderna's use of Arbutus' and Genevant's LNP technology in Spikevax, its COVID-19 vaccine, and mRESVIA, its RSV vaccine.
Moderna and Ross Stores Lead Stock Gainers on Wednesday
Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct catalyst.
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang
Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing it to focus on its pipeline.
Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline
The deal would provide ‘certainty' for Moderna's vaccine portfolio.
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences , and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its COVID-19 vaccine possible, the companies said on Tuesday.
Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash
Moderna ( MRNA ) stock has shed roughly 90% of its value since its 2021 peak. When I wrote about the Moderna stock setup last week, shares sat around $50.
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines.
Moderna's Covid-Flu Vaccine Recommended for Approval in EU
The recommendation from regulators paves the way for the shot's approval in the European Union at a time the company is facing scrutiny in the U.S.
